FP290
2123
Dr.Ksheeraja Y
| Membership No | Author Name | Mobile | |
|---|---|---|---|
| 4174MW | Dr.Meghdeep J Patil | meghdeeppatil55@gmail.com | 9972555660 |
Cornea, Ocular Surface and External Eye Diseases
Speeding with the Osmotic Edge:Isotonic vs Hypotonic Riboflavin in Accelerated Corneal Cross-Linking
ISOTONIC VS HYPOTONIC RIBOFLAVIN IN ACCELERATED CXL FOR KERATOCONUS Study Design: Prospective comparative observational study. Purpose: Compare isotonic vs hypotonic riboflavin in epithelium-off accelerated CXL. Methods: 30 eyes (n=15/group). Group A (thinnest corneal thickness ≥400µm): isotonic riboflavin; Group B (<400µm): hypotonic riboflavin. CXL at 9mW/cm² for 10 min. BCVA, keratometry, and endothelial parameters assessed at 3, 6, 12 months. Results: Keratometric stabilization in both groups by 6 months. BCVA improved by one Snellen line in 80%. No astigmatic progression >1D at 12 months. Endothelial parameters (cell density, CV, SD, hexagonality) were not statistically significant pre-op vs post-op (p>0.05). Conclusion: Marginally inferior postoperative BCVA in hypotonic (<6/12) vs isotonic group (6/6–6/12) reflects baseline disease severity, not treatment failure. Clinical Implication: Hypotonic riboflavin safely extends CXL eligibility to thin corneas with comparable outcomes.
No Co-Author Selected